Pure Global
NCT05515458

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
Chipscreen Biosciences, Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Renal Impairment
Drug/Device/Intervention
Chiglitazar
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chipscreen Biosciences, Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 30, 2022
End date
Dec 30, 2023
Enrollment
24 participants
Primary outcome

Cmax,AUC0-t and AUC0-inf

Summary

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic
 (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with
 renal impairment compared to subjects with normal renal function.

ICD-10 classifications
Renal failureDisorders resulting from impaired renal tubular functionDisorder resulting from impaired renal tubular function, unspecifiedOther disorders resulting from impaired renal tubular functionAcute renal failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05515458
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05515458 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chipscreen Biosciences, Ltd. and is currently Not yet recruiting. The study focuses on Renal Impairment. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.